Agility and adaptability support strategic growth
Financial highlights Q4 2020
- Net revenue amounted to 12,9 MSEK (9,6), an increase of 35 percent over the same period 2019 and an increase of 19 percent over the third period of 2020.
- EBITDA amounted to -10,8 MSEK (-11,4).
- Net result after taxes amounted to -20,8 MSEK (-15,1).
-
Earnings per share was -
0,37 SEK (-0,27). - Cash Balance amounted to 78,8 MSEK (19,4).
- Average Daily Treatment Revenue (ADTR)* was 130 TSEK (105),an increase of 23 percent over the same period in 2019 and an increase of 20 percent compared to the third quarter of 2020.
- Write down of inventory and C3 devices in the amount of 7,8 MSEK.
Financial highlights Full Year 2020
- Net revenue amounted to 46,6 MSEK (40,7), an increase of 15 percent over 2019.
- EBITDA amounted to -29,9 MSEK (-26,3).
- Net result after taxes amounted to -53,0 MSEK (-38,0).
-
Earnings per share was -
0,96 SEK (-0,76). - Cash Balance amounted to 78,8 MSEK (19,4).
- Average Daily Treatment Revenue (ADTR)* was 121 TSEK (98), an increase of 23 percent over 2019.
- Write off inventory and C3 devices 7,8 MSEK.
Significant events during the period
- The Company announced that the
American Medical Association will issue CPT® codes for scalp cooling effective1 July 2021 . This provides a pathway to reimbursement and creates significant opportunity for the Company's growth. Dignitana announced a directed share issues ofSEK 75 million before issue cost to accelerate growth and strategic transition to DigniCap.Dignitana announced the decision to write-off the value of all C3 devices in the amount of approximately 7,8 MSEK.
Business highlights during the period
- City of Hope selected DigniCap as the scalp cooling provider for 12 cancer treatment centers in
California . GenesisCare selectedDignitana as preferred scalp cooling provider for its rapidly expandingAustralia medical oncology centres.
Significant events after the period
Dignitana announced that the Extraordinary General Meeting onJanuary 11 approved the Board of Directors' resolution on the directed issue of shares made on22 December 2020 .
Business highlights after the period
- Mammazentrum Hamburg selected
DigniCap Delta to provide upgraded scalp cooling therapy. Dignitana announced the specific CPT codes for DigniCap which will be available to patients on1 July 2021 .- The Company highlighted new clinical guidelines from leading oncology organizations around the world which recommend scalp cooling.
- The Company has repaid in full the 20 MSEK unsecured loan received from Adma Förvaltnings AB in the third period of 2020.
Key Ratios
DIGNITANA GROUP | Q4 2020 | Q4 2019 | Full year 2020 | Full year 2019 |
Net revenues, TSEK | 12 928 | 9 572 | 46 629 | 40 699 |
Total revenues, TSEK | 13 006 | 10 062 | 49 956 | 42 546 |
Net profit after financial items, TSEK | -20 821 | -15 060 | -52 963 | -37 950 |
Cash and bank balances, TSEK | 78 770 | 19 433 | 78 770 | 19 433 |
Earnings per share before and after dilution, SEK | -0,37 | -0,27 | -0,96 | -0,76 |
Average Daily Treatment Revenue* TSEK | 130 | 105 | 120 | 98 |
* ADTR includes pay-per-treatment revenue from patients and facilities in the
"The Company's agility and adaptability have helped
-
The full report is attached to this release. All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that
For More Information Contact
About
https://news.cision.com/dignitana-ab/r/dignitana-ab-publishes-2020-year-end-report,c3288549
https://mb.cision.com/Main/2116/3288549/1374748.pdf
(c) 2021 Cision. All rights reserved., source